MAP Pharmaceuticals Issued U.S. Patent for Methods of Achieving Rapid Relief of Migraine and Minimizing Side Effects Based Upon Pharmacokinetic Profile
Links shared publicly online about this topic.
- 79total visits
MAP Pharmaceuticals Issued U.S. Patent for Methods of Achieving Rapid Relief of Migraine and Minimizing Side Effects Based Upon Pharmacokinetic Profile
Levadex (dihydroergotamine) is a new drug in development for the acute treatment of migraine. Levadex information includes news, clinical trial results and side effects.
View full resource at drugs.com
Tags: Migraine, Migraine Medication, Headache, Vascular Headache, Drug, Pharma, DHE 45
Most Recently Shared on August 12, 2011 at 3:04 am By:
MAP Pharmaceuticals Issued U.S. Patent for Methods of Achieving Rapid Relief of Migraine and Minimizing Si... http://bit.ly/n2CHeu #drug
Advertisement
